Imagine trying to patch a leaky pipe inside a wall without breaking the wall open. Current methods either require a huge hole in the wall or use a patch that often slips over time. This technology acts like a tiny, internal stapler that permanently locks the patch to the pipe wall from the inside, making it as secure as a hand-sewn stitch but without the major surgery.
Current AAA treatments force a choice between high-risk open surgery (durable) or low-risk EVAR (prone to migration and leaks). This creates a gap for a solution that is both minimally invasive and long-term durable.
A catheter-based endovascular suturing implant called Aortoseal that uses a self-stapling mechanism to secure stent grafts to the aortic wall.
If you are a device manufacturer dealing with the high failure rates of current EVAR grafts — this project developed Aortoseal, a self-stapling implant that provides the durability of open surgery with minimal invasiveness. It targets a global market of up to 4 million patients annually.
If you are a hospital operator dealing with high costs from secondary interventions and long patient stays — this project developed a fixation device that reduces the need for repeat procedures. This could contribute to projected EU healthcare savings of ~9 bn over 10 years.
If you are an insurer dealing with the high cost of lifelong CT monitoring for 78% of AAA patients — this project developed a durable sealing solution that reduces the need for constant monitoring and risky secondary interventions.
Based on available project data, the specific unit price of the Aortoseal device is not disclosed, though it is projected to contribute to ~9 bn in healthcare savings across the EU over 10 years.
The company has completed its Early Feasibility Study and is establishing research sites in Europe and the US, indicating it is moving toward larger-scale clinical validation.
Patents have been granted in the USA, Japan, and Australia, with expansion currently underway into additional global territories, including the EU.
Based on available project data, the project period runs until 2025-07-31, with current activities focused on establishing research sites for clinical trials.
Aortoseal is a catheter-based implant designed to seal and secure a stent graft to the aortic wall, fitting into the existing minimally invasive EVAR workflow.
The project is led by a single SME, Endoron Medical Ltd from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and clinical validation of their proprietary technology.
Contact Endoron Medical Ltd in Israel regarding clinical trial site partnerships.
Contact us to explore licensing opportunities for endovascular suturing technology.
